Previous 10 | Next 10 |
Gainers: Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...
Bausch Health Companies (NYSE: BHC ) initiated with Neutral rating and C$40 (7% upside) price target at Goldman Sachs. Shares up 2% premarket. More news on: Bausch Health Companies Inc., Centogene N.V., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ....
Galmed Pharmaceuticals Ltd (GLMD) Q3 2019 Earnings Conference Call November 06, 2019, 08:30 ET Company Participants Allen Baharaff - Chairman, CEO & President Yohai Stenzler - CFO & Controller Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Office...
Galmed (NASDAQ: GLMD ): Q3 GAAP EPS of -$0.21 beats by $0.09 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial for the ...
TEL AVIV, Israel , Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial fo...
TEL AVIV, Israel , Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the...
Quick Take 89bio ( ETNB ) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on developing and commercializing treatments for liver and cardio-metabolic diseases. ETNB plans to start Phase 2 trials in 2020 a...
TEL AVIV, Israel , Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic ...
Galmed Pharmaceuticals Ltd. (GLMD) Q2 2019 Earnings Conference Call August 5, 2019 8:30 A.M. ET Company Participants Allen Baharaff - President and Chief Executive Officer Yohai Stenzler - Chief Financial Officer Tali Gorfine - Chief Medical Officer Liat Hayardeny - Chief Scien...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for...
Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. A...